ReviewFunctional & integrative genomics2026
Multiscale predictive cellular modeling: integrating hypothesis grammars, digital twins, and multi-omics for In silico oncology and precision theranostics.
Review in Functional & integrative genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Computational Oncology of Chemotaxis-Driven Tumour-Immune Spatial Patterning and Stability.Bioengineering (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Predictive multiscale cellular modeling is emerging as a consequential direction in precision medicine, converging hypothesis grammars, digital twins, and integrative genomics to interrogate tumor-immune dynamics, therapeutic resistance, and cellular plasticity. This perspective synthesizes recent progress across these domains and critically maps their translational potential alongside their current limitations. Hypothesis grammars translate mechanistic theories into executable agent-based models (ABMs) and hybrid ODE-PDE systems, enabling rapid in silico hypothesis testing while lowering the authoring barrier for domain scientists. Patient-specific digital twins, driven by multi-omics data, employ stochastic ensemble methods to simulate clonal evolution and microenvironmental interactions, though prospective clinical validation of these capabilities remains at an early stage. Integrative genomics, leveraging algorithms such as SCODE and SimiC, infers causal gene regulatory networks (GRNs) using Bayesian variational autoencoders, embedding dynamic intracellular logic into tissue-scale simulations. Emerging applications include in silico oncology trials for optimizing checkpoint blockade and combination therapies. Large language models are being explored to enhance rule induction, while FAIR-compliant digital cell repositories aim to ensure reproducibility and reuse. Verification, validation, and uncertainty quantification (VVUQ) via Sobol sensitivity analysis and Kennedy-O'Hagan calibration are identified as essential components for addressing non-identifiability and supporting regulatory credibility. Federated learning is discussed as a means of mitigating privacy and bias concerns in multi-institutional settings. Together, these converging approaches outline a plausible pathway toward virtual clinical trials and adaptive theranostics, contingent on the prospective validation, data infrastructure, and governance frameworks that clinical deployment will require.
Indexed as
Identifiers
42213163What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.